Scinai Immunotherapeutics Ltd - ADR
SCNI
Market Cap$3.05M
Close$
Share Statistics
| Market cap | $3.05 Million |
|---|---|
| Enterprise Value | $3.24 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-16.69 |
| Beta | 2.47 |
| Outstanding Shares | 837,357 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.82 |
|---|---|
| PEG | 2.92 |
| Price to Sales | 2.22 |
| Price to Book Ratio | 0.2 |
| Enterprise Value to Revenue | 2.62 |
| Enterprise Value to EBIT | 0.46 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Scinai Immunotherapeutics Ltd
26 employees
CEO: Ron Babecoff biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and p...